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Background: Mutations in SCN9A, encoding the alpha subunit of the voltage-gated sodium channel (Nav1.7), have
caused severe pain disorders and congenital insensitivity to pain. The aim of this study was to validate the
previously reported association between a common non-synonymous polymorphism (R1150W, rs6746030) in SCN9A
and chronic widespread pain (CWP), in independent population-based cohorts.
Findings: Genotype data for rs6746030 was available in four population-based cohorts (EPIFUND, the European
Male Ageing Study (EMAS), the Framingham study and the Dyne Steel DNA Bank of Ageing and Cognition). Pain
was assessed using body manikins and CWP was scored using American College of Rheumatology (ACR) criteria in
all cohorts, except the Framingham study which assessed widespread pain (WP) using ACR criteria on a joint pain
homunculus. Controls were subjects who reported no pain. Logistic regression (additive genetic model) was used
to test for association between rs6746030 and CWP compared to controls, adjusting for study centre in EMAS.
Generalised estimating equation regression was used to test for association between rs6746030 and WP, whilst
accounting for relatedness between subjects in the Framingham study.
Genotype data for rs6746030 was available for 1071 CWP cases and 3212 controls. There was no significant
association between CWP and rs6476030 in individual cohorts or when combined in a fixed-effects meta-analysis
(Odds Ratio = 0.96 (95% confidence interval 0.82, 1.11) p = 0.567).
Conclusions: In contrast to a previous study, no association between a non-synonymous polymorphism in SCN9A
and CWP was observed in multiple population-based cohorts.
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Population-based cohortsIntroduction
SCN9A encodes an alpha subunit of the voltage-gated
sodium channel Nav1.7, which is expressed primarily in
nociceptive dorsal root ganglia (DRG) neurons and is
involved in the production of action potentials. Gain-
of-function mutations in SCN9A have caused a number
of severe pain syndromes through increased activity of* Correspondence: Kate.holliday@manchester.ac.uk
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reproduction in any medium, provided the orthe channel and loss-of-function mutations in SCN9A
have caused congenital insensitivity to pain [1].
Many complex trait susceptibility genes contain muta-
tions causing severe monogenic disorders with phenotypic
similarity in families. Consequently, it has been hypothe-
sised that common variation in SCN9A may influence pain
perception and susceptibility to chronic pain disorders. A
non-synonymous single nucleotide polymorphism (SNP),
rs6746030G!A, in SCN9A which causes an arginine(R)
to tryptophan(W) substitution, was recently associated
with increased pain scores in subjects with clinical painsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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experimental pain in healthy individuals and a non-
significant increase in post-operative pain scores [2]. The
1150 W allele has been shown to depolarise activation
and increase the firing rate in DRG neurons in response
to depolarisation [3] and steeper voltage dependence for
slow inactivation for 1150 W compared to 1150R has been
reported suggesting that the variant allele may make
neurons more sensitive to painful stimuli [2].
Valdes et al. (2011) failed to validate the association
between rs6746030 and pain scores in OA, reported by
Reimann et al. (2010), despite a larger study sample.
They did, however, report an increased odds of reporting
widespread pain (WP) with the A allele [4]. The aim of
this study was to validate the Valdes et al. (2011) finding
to determine if a putative functional polymorphism,
rs6746030, in SCN9A is associated with CWP.
Methods
Data was utilised from four population-based cohorts. The
Framingham study is a longitudinal multi-generational
study conducted in Framingham, Massachusetts, USA
since 1948. Pain data was collected at exam 22 in the ori-
ginal cohort and at exams 5–7 for the offspring cohort.
In the European Male Ageing Study (EMAS), men aged
40–79 years were recruited from population registers in
8 European centres [5]. Ethical approval for the study
was obtained at the co-ordinating centre and each par-
ticipating centre. [6]. In the EPIFUND cohort, subjects
aged 25–65 years were recruited via three primary care
practices in North-West England. Ethical approval was
obtained from Manchester local research ethics commi-
tee. The Dyne Steele DNA bank for ageing and cognition
(DSDBAC) includes elderly individuals participating in a
longitudinal study of cognition recruited via advertise-
ments in Manchester and Newcastle, UK, in 1983 [6].
Pain questionnaires were sent to subjects remaining in
the cohort in 2007 (aged 67–96 years). Ethical approval
was obtained from the University of Manchester. All
participants gave informed consent.
Pain status was assessed using a questionnaire and
joint pain homunculus in the Framingham Study. Sub-
jects were scored as having WP if they reported pain in
joints in contra-lateral body quadrants, above and below
the waist and in the axial skeleton in accordance with
American College of Rheumatology (ACR) criteria. In
the other cohorts, pain was assessed using a question-
naire and body manikins on which subjects shaded the
site of any pain and chronic widespread pain (CWP),
WP present for at least 3 months, was scored using ACR
criteria. Controls were subjects who reported no pain.
In silico genotype data for rs6746030 was utilised for the
Framingham and DSDBAC cohorts. The Framingham
SNP Health Association Resource (SHARe) projectgenotyped 9274 participants using the Affymetrix 500 K
mapping array and the Affymetrix 50 K supplemental
arrays, 3850 of which met sample quality controls
requirements (individuals were excluded if they were
genotyped for < 95% of SNPs, had excess heterozygosity
or >100 mendelian errors) and had pain data available.
DSDBAC was genotyped using the Illumina610-Quadv1
chip. 602 subjects passed sample QC (individuals were
excluded if they were genotyped for <95% of SNPs, for
gender discrepancy, relatedness (Identitiy By Descent
(IBD) sharing >0.25) and evidence of non-Caucasian an-
cestry (by multi-dimensional scaling)) and had pain data
available. Rs6746030 was genotyped using the Sequenom
iPLEX Gold massARRAY platform (Sequenom Inc, San
Diego, USA) following the manufacturer’s instructions
in EPIFUND and EMAS.
Generalised estimating equation regression was used
to test for association between rs6746030 and WP in the
Framingham study under an additive genetic model,
accounting for relatedness between subjects and using
genomic control to adjust for population stratification in
R. Logistic regression under an additive genetic model
was used to test for association between rs6746030 and
CWP in the other cohorts in PLINK [7] adjusting for
study centre in EMAS. Effect estimates were combined
in meta-analysis using STATA v10.
Results
In silico genotype data for rs6746030, met SNP qual-
ity control criteria in the Framingham (genotyped in
≥97% of subjects, Hardy-Weinberg Equilibrium (HWE)
p > 1 x10-6) and DSDBAC (genotyped in ≥98% of sub-
jects, HWE p> 1 x10-3) cohorts. Rs6746030 was geno-
typed in EPIFUND and EMAS in 100% of subjects with
HWE p> 0.05. The characteristics of the cases (n = 1071)
and controls (n = 3214) in the four cohorts are shown in
Table 1. Prevalence of CWP and being pain-free varied
between cohorts in accordance with age, gender and
study design.
With 1-sided 5% type I error and a minor allele fre-
quency (MAF) of 13%, this study had 80% power to de-
tect an odds ratio of 1.20 for CWP compared to pain-free
controls and 99% power to detect an odds ratio of 1.40 as
observed by Valdes et al. (2011), calculated using Quanto
[8]. There was a non-significant decrease in the preva-
lence of the A allele in subjects with WP and CWP in
the Framingham and DSDBAC cohorts, respectively.
There was a non-significant increase in prevalence of
the A allele in CWP cases in EMAS, which did not sig-
nificantly differ between study centres (p = 0.30), and no
difference in prevalence of the A allele between cases
and controls in EPIFUND. There was no evidence of
heterogeneity (I2 = 0%, p = 0.891) between cohorts, there-
fore a fixed-effects meta-analysis was used to combine
Table 1 Characteristics of the study populations
Cohort Framingham EMAS EPIFUND DSDBAC
Country USA Pan-European UK UK
Pain assessment Homunculus Manikin Manikin Manikin
Casesa
N subjects (%) 572 (15) 208 (8) 197 (18) 94 (16)
Age, years mean (SD) 60.4 (11.4) 60.5 (10.9) 51.1 (9.0) 79.6 (4.7)
Gender (% female) M/F (67) M M/F (72) M/F (86)
Controlsb
N subjects (%) 1587 (41) 973 (39) 395 (35) 259 (43)
Age, years mean (SD) 57.9 (13.1) 59.7 (10.9) 48.2 (10.3) 80.5 (5.7)
Gender (% female) M/F (51) M M/F (55) M/F (71)
a cases are subjects with chronic widespread pain (ACR criteria) except Framingham which is widespread pain; b controls are pain-free subjects.
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(95% confidence interval 0.82, 1.11) p = 0.567 per A al-
lele of rs6746030 on CWP (Figure 1).
Discussion
This study attempted to validate an association between
rs6746030 in the SCN9A gene and reporting pain at
multiple body sites in four independent cohorts. No evi-
dence of association with CWP was observed, conflicting
with a previous report that the minor (A) allele was
associated with increased odds of reporting pain in mul-
tiple sites [4].
The findings of this study and the Valdes et al. study
are equivocal; this may be due to a number of factors.
Firstly, the criteria used to classify cases with widespread
pain and controls differed between studies. The majority
(76.1%) of subjects in the Valdes et al. study were
recruited as part of case–control study of OA with the
remainder recruited from two population based studies.
Subjects were classified as having multiple regional pain
using different definitions in each sub-study, however,Figure 1 Forest plot for the odds ratio (95%CI) of the A allele of rs67
(fixed-effects). Odds ratios (■) and their 95% confidence intervals (CI) are
combined (in a fixed effects meta-analysis) is shown by the dashed line, w
intervals. The line at 1 represents the null. If the 95%CI crosses this line thethe authors reported no between-study heterogeneity.
Secondly, the prevalence of WP/CWP reported here,
8-18% was higher than in Valdes et al. (2011), 4-9%. It is
possible that the case phenotype in the present study was
more heterogeneous and/or includes subjects with less
severe or disabling pain and rs6746030 may associate
with severe/disabling widespread pain. Thirdly, in the
present study, controls were subjects reporting no pain
to eliminate the possibility of a false negative association
occurring due to the presence of regional pain in the
control group. However, in the Valdes et al. study control
subjects may or may not have had pain suggesting that
the association was specifically with multi-site pain
rather than pain per se. Finally, the original observation
was adjusted for age, sex and body mass index. Indivi-
duals with widespread pain have increased rates of other
painful disorders such as irritable bowel syndrome and
chronic oro-facial pain and the results from the Valdes
et al. (2011) study may reflect a higher “pain-load” that
was not detected in this study due to phenotype
heterogeneity.46030 on CWP by cohort and combined in a meta-analysis
shown for the effect in each cohort. The odds ratio for all cohorts
ith the extremes of the diamond shape representing confidence
n there is no association.
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ment and definition differed between cohorts. A joint
pain assessment, which did not include chronicity, was
used for the Framingham study. Consequently, cases in
the Framingham cohort may represent a different group
to the other cohorts; however, the majority of chronic
pain reported is at joint sites and widespread pain is usu-
ally chronic. In addition, the controls in the Framingham
cohort may have had some pain at non-joint sites and
may not represent a truly pain-free group. The cohorts
also differed in age, gender, geographic location and indi-
vidual cohorts lacked power to detect an association. No
data on ethnicity was available for the EPIFUND cohort,
however, the majority are thought to be white British [9]
and only information on self-reported ancestry was avail-
able in EMAS.
CWP will resolve in some individuals and persists in
others. Genetic factors may play a more important role
in persistent and/or disabling CWP; although, this has
yet to be demonstrated. If so, comparing individuals with
persistent and/or disabling CWP to pain-free controls
may be a more powerful approach to identifying suscep-
tibility loci for chronic pain. Given that pain was assessed
at a single time-point in the majority of the cohorts
utilised in this study and associated disability data was
not available, we were unable to test this in the current
study; however, this approach could be fruitful if adopted
in future studies.
Our findings also conflict with those of Reimann et al.
(2010), who observed that the A allele of rs6746030 was
associated with reporting higher pain scores in subjects
with a variety of clinical pains and increased pain sensi-
tivity in healthy individuals [2]. This may suggest that
the SNP is associated with the severity of pain reported
within a pain state rather than the presence of wide-
spread pain, as tested here. However, Valdes et al. (2011)
did not observe an association between rs6746030 and
pain scores in knee OA in over 1000 subjects [4].
The lack of association reported here, despite the
large sample size (1071 cases and 3214 controls), sug-
gests that this SNP is not a susceptibility marker for
CWP. Other SNPs within the gene or in regulatory
regions for SCN9A may be important in CWP suscepti-
bility and may influence the effect of rs6746030 but have
yet to be investigated. Environmental factors, not con-
trolled for in the present study could also potentially
mask a true effect.
In conclusion, we find no evidence of association for
rs6746030 in SCN9A, previously shown to play a role in
pain perception, with CWP in a meta-analysis of four
population-based cohorts. However, SCN9A remains a
strong candidate gene for chronic pain and is worthy of
investigation in large-scale genetic association studies.
Harmonisation of pain phenotypes to allow cohorts tobe combined is required to facilitate such studies and to
elucidate the genetic risk factors for chronic pain.
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